A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD

Recruiting

Phase 3

AOC 1020A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD

Sponsor:

Avidity Biosciences, Inc.

Code:

NCT07038200

Conditions

Facioscapulohumeral Muscular Dystrophy

FSHD

FSHD - Facioscapulohumeral Muscular Dystrophy

FSHD1

FSHD2

Eligibility Criteria

Sex: All

Age: 16 - 70

Healthy Volunteers: Not accepted

Interventions

AOC-1020

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-08. This information was provided to ClinicalTrials.gov by Avidity Biosciences, Inc. on 2025-10-20.